A novel monoclonal antibody KMP1 has potential antitumor activity of bladder cancer by blocking CD44 in vivo and in vitro

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study

(2017) Elizabeth R Plimack et al.   LANCET ONCOLOGY

CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma

(2016) Anna Kakehashi et al.   CANCER SCIENCE

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Clinical significance of CD44 variant 9 expression as a prognostic indicator in bladder cancer

(2016) Keita Kobayashi et al.   ONCOLOGY REPORTS

Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality

(2016) Masayuki Hagiwara et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

GALNT1-Mediated Glycosylation and Activation of Sonic Hedgehog Signaling Maintains the Self-Renewal and Tumor-Initiating Capacity of Bladder Cancer Stem Cells

(2015) C. Li et al.   CANCER RESEARCH

BCMab1, A Monoclonal Antibody against Aberrantly Glycosylated Integrin  3 1, Has Potent Antitumor Activity of Bladder Cancer In Vivo

(2014) C. Li et al.   CLINICAL CANCER RESEARCH

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base

(2013) Angela B. Smith et al.   BJU INTERNATIONAL

CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence

(2013) K Hirata et al.   BRITISH JOURNAL OF CANCER

Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non–muscle invasive bladder cancer

(2013) Andrew J. Lightfoot et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Expression of a tumor-associated gene, LASS2, in the human bladder carcinoma cell lines BIU-87, T24, EJ and EJ-M3

(2013) QINGHUA ZHAO et al.   Experimental and Therapeutic Medicine

Therapeutic Antibodies Against Cancer

(2012) Mark J. Adler et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Long-Term Survival Outcomes with Intravesical Docetaxel for Recurrent Nonmuscle Invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy

(2012) LaMont J. Barlow et al.   JOURNAL OF UROLOGY

New Strategies in Muscle-Invasive Bladder Cancer: On the Road to Personalized Medicine

(2011) J. B. Shah et al.   CLINICAL CANCER RESEARCH

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Critical Roles of Mucin 1 Glycosylation by Transactivated PolypeptideN-Acetylgalactosaminyltransferase 6 in Mammary Carcinogenesis

(2010) Jae-Hyun Park et al.   CANCER RESEARCH

The DC-SIGN family member LSECtin is a novel ligand of CD44 on activated T cells

(2010) Li Tang et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Bacillus Calmette-Guérin With or Without Interferon α-2b and Megadose Versus Recommended Daily Allowance Vitamins During Induction and Maintenance Intravesical Treatment of Nonmuscle Invasive Bladder Cancer

(2010) Kenneth G. Nepple et al.   JOURNAL OF UROLOGY

Antibody recognition of a unique tumor-specific glycopeptide antigen

(2010) C. L. Brooks et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bladder cancer

(2009) Donald S Kaufman et al.   LANCET

Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts

(2008) Albana Cumashi et al.   CANCER LETTERS

Biomolecular Characterization of CD44-Fibrin(ogen) Binding

(2008) Christina S. Alves et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Involvement of CD44, a molecule with a thousand faces, in cancer dissemination

(2008) David Naor et al.   SEMINARS IN CANCER BIOLOGY